A detailed history of Northern Trust Corp transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 494,860 shares of SAGE stock, worth $2.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
494,860
Previous 490,525 0.88%
Holding current value
$2.71 Million
Previous $5.33 Million 33.04%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$7.02 - $13.08 $30,431 - $56,701
4,335 Added 0.88%
494,860 $3.57 Million
Q2 2024

Aug 14, 2024

SELL
$10.58 - $17.9 $378,848 - $640,963
-35,808 Reduced 6.8%
490,525 $5.33 Million
Q1 2024

May 14, 2024

SELL
$18.62 - $26.95 $303,934 - $439,904
-16,323 Reduced 3.01%
526,333 $9.86 Million
Q4 2023

Feb 13, 2024

SELL
$17.1 - $22.26 $1.49 Million - $1.94 Million
-87,122 Reduced 13.83%
542,656 $11.8 Million
Q3 2023

Nov 13, 2023

SELL
$16.75 - $48.98 $92,543 - $270,614
-5,525 Reduced 0.87%
629,778 $13 Million
Q2 2023

Aug 11, 2023

BUY
$40.65 - $59.54 $1.62 Million - $2.37 Million
39,871 Added 6.7%
635,303 $29.9 Million
Q1 2023

May 15, 2023

SELL
$37.27 - $46.57 $387,347 - $484,002
-10,393 Reduced 1.72%
595,432 $25 Million
Q4 2022

Feb 13, 2023

SELL
$32.2 - $43.61 $12,590 - $17,051
-391 Reduced 0.06%
605,825 $23.1 Million
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $72,855 - $97,660
2,257 Added 0.37%
606,216 $23.7 Million
Q2 2022

Aug 12, 2022

BUY
$27.52 - $37.99 $9.4 Million - $13 Million
341,525 Added 130.14%
603,959 $19.5 Million
Q1 2022

May 13, 2022

SELL
$30.71 - $45.71 $241,964 - $360,149
-7,879 Reduced 2.91%
262,434 $8.69 Million
Q4 2021

Feb 08, 2022

BUY
$37.06 - $47.11 $48,437 - $61,572
1,307 Added 0.49%
270,313 $11.5 Million
Q3 2021

Nov 15, 2021

SELL
$40.26 - $57.37 $225,254 - $320,985
-5,595 Reduced 2.04%
269,006 $11.9 Million
Q2 2021

Aug 13, 2021

SELL
$54.88 - $79.29 $246,356 - $355,932
-4,489 Reduced 1.61%
274,601 $15.6 Million
Q1 2021

May 12, 2021

SELL
$70.65 - $96.76 $900,081 - $1.23 Million
-12,740 Reduced 4.37%
279,090 $20.9 Million
Q4 2020

Feb 11, 2021

SELL
$58.41 - $89.06 $444,324 - $677,479
-7,607 Reduced 2.54%
291,830 $25.2 Million
Q3 2020

Nov 16, 2020

SELL
$41.13 - $62.45 $246,163 - $373,763
-5,985 Reduced 1.96%
299,437 $18.3 Million
Q2 2020

Aug 14, 2020

BUY
$25.95 - $43.15 $1.11 Million - $1.84 Million
42,652 Added 16.23%
305,422 $12.7 Million
Q1 2020

May 14, 2020

BUY
$26.15 - $77.24 $304,464 - $899,305
11,643 Added 4.64%
262,770 $7.55 Million
Q4 2019

Feb 14, 2020

SELL
$60.18 - $154.77 $1.98 Million - $5.1 Million
-32,961 Reduced 11.6%
251,127 $18.1 Million
Q3 2019

Nov 13, 2019

BUY
$140.29 - $189.96 $1.33 Million - $1.8 Million
9,468 Added 3.45%
284,088 $39.9 Million
Q2 2019

Aug 13, 2019

BUY
$157.85 - $183.09 $2.39 Million - $2.77 Million
15,119 Added 5.83%
274,620 $50.3 Million
Q1 2019

May 13, 2019

BUY
$89.33 - $163.65 $3.51 Million - $6.44 Million
39,325 Added 17.86%
259,501 $41.3 Million
Q4 2018

Feb 12, 2019

SELL
$81.94 - $139.71 $14,175 - $24,169
-173 Reduced 0.08%
220,176 $21.1 Million
Q3 2018

Nov 14, 2018

SELL
$138.11 - $169.04 $224,704 - $275,028
-1,627 Reduced 0.73%
220,349 $31.1 Million
Q2 2018

Sep 18, 2018

SELL
$140.36 - $175.76 $380,375 - $476,309
-2,710 Reduced 1.21%
221,976 $34.7 Million
Q2 2018

Aug 14, 2018

SELL
$140.36 - $175.76 $37.7 Million - $47.3 Million
-268,909 Reduced 54.48%
224,686 $35.2 Million
Q1 2018

May 09, 2018

BUY
$152.15 - $192.33 $7.52 Million - $9.51 Million
49,437 Added 11.13%
493,595 $79.5 Million
Q4 2017

Feb 14, 2018

BUY
$60.72 - $167.34 $1.94 Million - $5.35 Million
31,984 Added 7.76%
444,158 $73.2 Million
Q3 2017

Nov 13, 2017

BUY
$61.4 - $88.52 $25.3 Million - $36.5 Million
412,174
412,174 $25.7 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.